Regeneron Pharmaceuticals, a maker of synthetic biologic treatments, is acquiring Decibel Therapeutics, developer of gene therapies to treat hearing loss and balance disorders. . . . → Read More: Regeneron Acquires Hearing Loss Biotech in $213M Deal
|
|||||
Regeneron Pharmaceuticals, a maker of synthetic biologic treatments, is acquiring Decibel Therapeutics, developer of gene therapies to treat hearing loss and balance disorders. . . . → Read More: Regeneron Acquires Hearing Loss Biotech in $213M Deal A women’s health biotechnology company is partnering with a Brazilian drug maker to evaluate a precision target and treatment for ovarian health disorders. . . . → Read More: Companies to Assess Ovarian Health Biotech Drug The developer of a biologic drug-making process with engineered plant crops is collaborating with a vertical farming company to create a network of biologics production facilities. . . . → Read More: Companies Partner on Fast Production of Biologics in Plants A group of academic and industry researchers exhibited in lab cells and mice a more direct delivery technique that could make gene therapies more accessible and inexpensive. . . . → Read More: Streamlined Gene Therapy Delivery Process Demonstrated A treatment for HIV taken just once, using the genome-editing technology Crispr, is receiving fast-track designation from the U.S. Food and Drug Administration. . . . → Read More: One-Time Crispr HIV Therapy Given Fast-Track Status A synthetic biology company is receiving a contract with the U.S. advanced defense research agency to devise a high-speed localized process for making therapeutic proteins. . . . → Read More: Darpa Seeking On-Demand, Distributed Production of Proteins A developer of diagnostics for infectious and other diseases is receiving a National Institutes of Health contract to advance a single at-home test for multiple respiratory diseases. . . . → Read More: NIH Funding Single Home Test for Covid-19, Influenza, RSV A company using a process it says can produce synthetic genes with greater accuracy for research and clinical applications is raising $10 million in its first venture round. . . . → Read More: Synthetic DNA Company Gains $10M in Venture Round Results of a small clinical trial show genetically altered T-cells from patients with myasthenia gravis are well tolerated and reduce symptoms of the disease. . . . → Read More: Engineered T-Cells Shown Safe, Reduce Myasthenia Gravis A new U.S. patent, licensed to a start-up biotechnology company, describes processes for linking together chains of synthetic peptides into therapeutic proteins. . . . → Read More: Patent Issued for Synthetic Peptide Chain Techniques |
|||||
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |